erial No FORM PTO 1449 (modific Atty. Docket No. 09/647,278 X-11965 INFORMATION DISCLOSURE CITEXION Applicants IN AN APPLICATION MAY 1 6 2001 MAY 1 8 2001 Janet M. Hock Group Filing Date TECH CENTER 1600/290( 1654 (646 9/26/2000 U.S. PATENT DOCUMENTS Class Sub-Filing Date Document Number Date Name Examiner II class **Initial** Appropriate 4/25/78 4,086,196 Tregear RLi 4,698,328 10/6/87 Neer et al. AB RLI AC AD FOREIGN PATENT DOCUMENTS Sub-Translation Class Document Number Date Country class yes no 09.04.98 WO BA 98/14478 RLi 99/12561 18.03.99 WO RLi 19.03.96 BC 08073376 RLi OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Hirano T, et al., "Anabolic Effects of Human Biosynthetic Parathyroid CA Hormone Fragment (1034), LY333334, on Remodeling and Mechanical RLi Properties of Cortical Bone in Rabbits," Journal of Bone and Mineral Research, Vol. 14, No.4, 536-545 (1999). Lindsay, R. et al., "Randomised controlled study of effect of СВ parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis, " The Lancet, Vol. 350, 550-555 (1997). Macgill, K. et al., "Vascular Effects of PTHrP (1-34) and PTH (1-34) in CC the Human Fetal-Placental Circulation," Placenta, Vol. 18, 587-592 (1997).Lindsay, R. et al., "Subcutaneous Administration of the Amino-Terminal CD Fragment of Human Parathyroid Hormone- (1-34): Kinetics and Biochemical Response in Estrogenized Osteoporotic Patents, " Journal of Clinical Endocrinology and Metabolism, Vol. 77, No. 6, 1535-1539 Lane, N. et al., "Parathyroid Hormone Treatment Can Reverse CE Corticosteroid-Induced Osteoporosis, " J. Clin. Invest., Vol. 102, No. 8, 1627-1633 (October 1998). Cosman F. et al., "Is Parathyroid Hormone a Therapeutic Option for CF Osteoporosis? A Review of the Clinical Evidence, " Calcified Tissue International, Vol. 62, 475-480 (1998). Hesch, R.D. et al., "Results of a Stimulatory Therapy of Low Bone CG Metabolism in Osteoporosis with (1-38)hPTH and Diphosphonate EHDP," Klinische Wochen Schrift, Vol. 66, 976-984 (1988). Cosman, F., et al, "Estrogen Protection against Bone Resorbing Effects CH of Parathyroid Hormone Infusion, " Annals of Internal Medicine, Vol. 118, No. 5, 337-343 (1993) DATE CONSIDERED EXAMINER 7/29/2002 Ruisians \*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

ヒラ

FORM PTC	1449	Andified No.	Atty. Docket No. X-11965	Serial No 09/647,278				
INFORMAT		CLOSURE CITATION	Applicant Janet M. Hock	[ ++				
			Filing Date 9/26/2000	Group 1654   646				
	T CI T	Ejersted, C. et a	1., "Human Parathyroid He	ormone (1034) and (1084)				
RLi		Increase the Mech	anical Strength and Thic	kness of Cortical Bone in				
KLI	1	Rats," " Journal (1993).	of Bone and Mineral Rese	arch, Vol. 3, No. 9, 1097-1101				
	CJ	Jerome, C.P. et a	1., "Effect of Treatment	For 3 Months With Human				
}	"	Parathyroid Hormo	ne 1-34 Peptide in Ovari	ectomized Cynomolgus Monkeys				
	<del>   </del>		(Macaca fascicularis), " Bone, Vol. 17, No.4, Supplement, 415S-420S (1995).  Dempster D.W., et al., "Anabolic Actions of Parathyroid Hormone on Bone," Endocrine Reviews, Vol. 14, No. 6, 690-709, (1993).					
	CK	Demoster D.W., et						
		Bone, " Endocrine						
	CL	Fujita, T., et al	., "Effect of an Intermi	ttent Weekly Dose of Human				
}		Parathyroid Hormo	ne (1-34) on Osteoporosi	s: A Randomized Double-Masked				
l		Prospective Study Using Three Dose Levels, "Osteoporosis International, Vol. 9, 296-306 (1999).						
	CM	Wesch R D et al	al "Increase of Vertebral Density by Combination					
		Therapy with Puls	atile 1-38hPTH and Seque	the 1-38hPTH and Sequential Addition of Calcitonin				
		Nasal Spray in Os	teoporotic Patients," Ca	porotic Patients," Calcified Tissue International,				
<del></del>	CN	Vol. 44, 176-180,	(1989).	"A Randomized Controlled Trial to Compare the				
	CN	Efficacy of Cycli	cal Parathyroid Hormone	Versus Cyclical Parathyroid				
		Hormone and Seque	ntial Calcitonin to Impr	ove Bone Mass in Postmenopausa				
Ì		Women with Osteop	orosis," Journal of Clin 82, No. 2, 620-628, (199	ical Endocrinology and 7\				
	co	Reeve J et al	"Anabolic Effect of Hum	an Parathyroid Hormone Fragmer				
1		on Trabecular Bon	e in Involutional Osteop	orosis: A Multicentre Trial,"				
		British Medical J	Tournal, Vol. 280, 1340-1	n Changes in Femoral Bone				
	CP	Density and Calci	um Balance in Patients w	ith Involutional Osteoporosis				
		Treated with Huma	Treated with Human Parathyroid Hormone Fragment (hPTH 1034), "Metabolic Bone Disease & Related Research, Vol. 2, 331-334, (1981).					
	<u> </u>	Bone Disease & Re	elated Research, Vol. 2,	Osteoporosis with Added				
l	CQ	Hormone Replaceme	ent Therapy: Biochemical	, Kinetic and Histological				
1	ol. 1, 162-170, (1991).							
	CR	Reeve J et al.	"Human Parathyroid Pept	uman Parathyroid Peptide Treatment of Vertebral porosis International, Vol. 1 Supplement, S199-203,				
		Osteoporosis, " Os (1993).	steoporosis International	, Vol. 1 Supplement, 5199-203,				
	cs	Slovik, D. M. et	al., "Restoration of Spi	nal Bone in Osteoporotic Men 1				
- 1		Treatment With Hu	man Parathyroid Hormone	(1-34) and 1,25-				
		Dihydroxyvitamin 4, 377-381, (1986		Mineral Research, Vol. 1, No.				
	CT	Neer R M et al.	. "The Use of Parathyroi	d Hormone Plus 1, 25-				
İ		dihydroxyvitamin	D to Increase Trabecular	Bone in Osteoporotic Men and				
	<u>                                     </u>	Postmenopausal Wo	omen, " Osteoporosis, Vol.	man 1-34 Parathyroid Peptide				
1	CŪ	Alternating With	Calcitriol Paradoxically	Reduce Bone Remodelling in				
ļ		Spinal Osteoporos	sis," European journal of	Clinical Investigation, Vol.				
	<u> </u>	17, 421-428, (198	37).	sis with Human Parathyroid				
	CA	Reeve, J. et al., Peptide and Obser	rvations on Effect of Soc	lium Fluoride, BMJ, Vol. 301,				
	<u>                                     </u>	134-318 (1990).						
	CW	Dempster, D.W. et	al., "Anabolic Actions Reviews, Vol. 14, No.6,	of Parathyroid Hormone on				
duplicate	of CK							
	СХ	Riggs, B.L. et al	1., "Formation-Stimulating	ng Regimens Other Than Sodium Ine, Vol. 95 supplement 5A, 5A				
RLi		Fluoride," The An 62S - 5A-68S (199		voi. 33 supprement day sa				
L		1020 32. 000 (13.	DATE CONSIDER	7/29/2002				

MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

	(MA)	1 6 20%.	•4	Sheet 3 of _				
FORM PTO	星	.6,	Atty. Docket No. X-11965	Serial No 09/647,278				
INFORMAT: IN AN API		CLOSURE CITATION	Applicant Janet M. Hock					
			Filing Date 9/26/2000	Group <del>1654</del>   646				
	CY	Neer, D.M. et al., "	Treatment of Postmenop	ausal Osteoporosis with Daily oporosis International, Vol.				
RLi		Supplement, S204-205	i, (1993).					
	CZ	Hormone: New Therap 386, (1995).	peutic Agents for Osteo	ng Fragments of Parathyroid porosis, "TiPS, Vol. 16, 382-				
	CAA	Increased Bone Mass	A Small Dose of Human Parathyroid Hormone (1034) in the Lumbar Vertebrae in Patients with Senile er Electrolyte Metab, Vol. 21, 232-235 (1995).					
	CAB	Reginster, J.Y. et a Involutional Osteopo	al., "Parathyroid Hormo prosis: Back to the Fu	ne in the Treatment of ture, "Osteoporosis				
	CAC	Smith, S.Y. et al., (1-84) (rhPTH, (1-84	l)) in Ovariectomized R	nt Human Parathyroid Hormone hesus Monkeys, " Journal of SA456 Abstract, S633, (1998).				
	CAD	Finkelstein, J.S. et discontinuation of l with endometriosis,"	al., "Increases in bo ong-term GnRH analog a	ne density after nd PTH administration in wome ineral Research, Vol. 23,				
	CAE	Finkelstein, J.S. et Discontinuation of I Releasing Hormone An The Journal of Clini	al., "Increases in Bo Daily Human Parathyroid Dalog Administration in	ne Mineral Density after Hormone and Gonadotriopin- Women with Endometriosis, " tabolism, Vol. 84, No.4, 1214				
	CAF	Fragment (hPTH 1-34) Trabecular and Corti Immunoassay, Proceed	in Osteoporosis: Opt cal Bone," Monoclonal lings of the 3 <sup>rd</sup> Interna	Human Parathyroid Hormone imizing the Anabolic Effect of Antibodies and Developments tional Conference on era, Italy, May 6-9, 1981.				
	CAG	Finkelstein, J.S. et						
	CAH	Finkelstein, J.S. et Bone Loss Induced by	al., "Parathyroid Hor	mone for the Prevention of The New England Journal of				
	CAI	Hodsman, A.B. et al. Prospects, "Chapter	, "Parathyroid Hormone	: The Clinical Experience ar				
<b>—</b>	CAJ	Hormone Followed by	<ul><li>al., "Treatment of Ost Alendronate. Bone Mark 5-S517, Abstract F451,</li></ul>	eoporosis with Parathyroid er Results," <i>Bone</i> , Vol. 23, (1998).				
	CAK	Lindsay, R. et al.,	"Randomised controlled	study of effect of				
uplicate of		parathyroid hormone postmenopausal women 350, 550-555 (1997).	n on oestrogen with ost	and fracture incidence among eoporosis, " The Lancet, Vol.				
	CAL							
	CAM							
	CAN							
	CAO							
i	CAP							
EXAMINER	<u> </u>	Ruixiang L.	DATE CONSIDERED	7/29/2002				
		Kushang L.		7/29 120° L				

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO 1449 (modified) A					Docket No. 5	Serial 09/647,		RF(	CEIV	<b>VED</b>	
INFORMATI IN AN APF	ON D	ISCLOSURE CITE I		Applic Janet	ants M. Hock				Y 18;	1	
		MAY 1 6 2001 7		Filing 9/26/2		Group 1654 (6	46	TECH CE		1	
		TRADEMARK OF	U.S. PA	TENT	DOCUMENTS						
Examiner Initial		Document Number	Date		Name	Class	Sub- class	Filing I: Approp	E		
RLi	AA	4,086,196	4/25/78	Tregea	ar						
RLi	AB	4,698,328	10/6/87	Neer 6	et al.					}	
	AC										
	AD									}	
	<del></del>		FOREIGN	PATENT	DOCUMENTS						
		Document Number	Date		Country	Class	Sub- class	Transl			
RLi	BA	98/14478	09.04.98	WO				yes	no_		
RL:	ВВ	99/12561	18.03.99	WO						1	
RLi	ВС	08073376	19.03.96	EP							
	отн	ER DOCUMENTS (Incl	uding Aut	hor, T	itle, Date, Pe	rtinent Pa	ges, Etc	2.)			
RLi	CA	Hormone Fra	Hirano T, et al., "Anabolic Effects of Human Biosynthetic Parathyroid Hormone Fragment (1034), LY333334, on Remodeling and Mechanical Properties of Cortical Bone in Rabbits," Journal of Bone and Mineral Research, Vol. 14, No.4, 536-545 (1999).								
	СВ	Lindsay, R. parathyroic postmenopau 350. 550-55	Lindsay, R. et al., "Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis," The Lancet, Vol. 350, 550-555 (1997).								
	CC	Macgill, K. the Human E	Macgill, K. et al., "Vascular Effects of PTHrP (1-34) and PTH (1-34) in the Human Fetal-Placental Circulation," Placenta, Vol. 18, 587-592 (1997).								
	CD	Lindsay, R. Fragment of Biochemical Clinical En (1993).	Lindsay, R. et al., "Subcutaneous Administration of the Amino-Terminal Fragment of Human Parathyroid Hormone- (1-34): Kinetics and Biochemical Response in Estrogenized Osteoporotic Patents," Journal of Clinical Endocrinology and Metabolism, Vol. 77, No. 6, 1535-1539								
	CE	Lane, N. et Corticoster	Lane, N. et al., "Parathyroid Hormone Treatment Can Reverse Corticosteroid-Induced Osteoporosis," J. Clin. Invest., Vol. 102, No. 8, 1627-1633 (October 1998).								
	CF	Cosman F. o Osteoporosi Internation	et al., "I s? A Rev aal, Vol.	Is Para view of 62, 47	thyroid Hormon the Clinical 5-480 (1998).	Evidence,"	Calcif.	ied Tiss	ue		
	CG	Hesch, R.D. Metabolism	et al., in Osteop	"Resul porosis	ts of a Stimul with (1-38)hF Vol. 66, 976-9	TH and Dip	hosphon	Low Bone ate EHDP	, "		
	СН	Cosman, F.	et al, v	Estrogone Inf	en Protection usion," Annals	against Bo	ne Reso	rbing Ef cine, Vo	fects 1.		
EXAMINER		Ruisiang L.		r	ATE CONSIDERE	7/29/2003					
MPEP 609;	Draw	ial if citation c line through cita th next communica	tion if n	ot in c	onformance and	ation is in d not consi	confordered.	mance wi Include	th copy		

	15	<u> </u>								
FORM PTO	1449	Ddified O	Atty. Docket No. X-11965	Serial No 09/647,278						
INFORMAT IN AN AP		LOSURE CITATION N	Applicant Janet M. Hock							
			Filing Date 9/26/2000	Group 1654 (646						
	CI		"Human Parathyroid Hor							
RLi	1	Rats," " Journal of 1 (1993).	Bone and Mineral Resear	ess of Cortical Bone in ch, Vol. 3, No. 9, 1097-1101						
	CJ	Parathyroid Hormone (Macaca fascicularis (1995).	)," Bone, Vol. 17, No.4	tomized Cynomolgus Monkeys , Supplement, 415S-420S						
	CK <sub>1</sub> ,	Bone, " Endocrine Rev.	iews, Vol. 14, No. 6, 6							
	CL	Parathyroid Hormone	(1-34) on Osteoporosis: ing Three Dose Levels,"	ent Weekly Dose of Human A Randomized Double-Masked Osteoporosis International,						
	CM	Hesch, R.D. et al., Therapy with Pulsati Nasal Spray in Osteon	Hesch, R.D. et al., "Increase of Vertebral Density by Combination Therapy with Pulsatile 1-38hPTH and Sequential Addition of Calcitonin Nasal Spray in Osteoporotic Patients," Calcified Tissue International, Vol. 44, 176-180, (1989). Hodsman, A.B. et al., "A Randomized Controlled Trial to Compare the Efficacy of Cyclical Parathyroid Hormone Versus Cyclical Parathyroid Hormone and Sequential Calcitonin to Improve Bone Mass in Postmenopausa Women with Osteoporosis," Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 2, 620-628, (1997).							
	CN	Hodsman, A.B. et al. Efficacy of Cyclical Hormone and Sequentia Women with Osteoporos								
	co	Reeve, J. et al., "Ar on Trabecular Bone in	Reeve, J. et al., "Anabolic Effect of Human Parathyroid Hormone Fragmen on Trabecular Bone in Involutional Osteoporosis: A Multicentre Trial," British Medical Journal, Vol. 280, 1340-1344, (1980).							
	СР	Density and Calcium Pareated with Human Pa	esp, R. et al., "The Relationship between Changes in Femoral Bone ensity and Calcium Balance in Patients with Involutional Osteoporosis reated with Human Parathyroid Hormone Fragment (hPTH 1034)," Metabolic one Disease & Related Research, Vol. 2, 331-334, (1981).							
	CQ	Hormone Replacement	et al., "hPTH 1-34 Treatment of Osteoporosis with Added lacement Therapy: Biochemical, Kinetic and Histological Osteoporosis International, Vol. 1, 162-170, (1991).							
	CR	Reeve, J. et al., "Hu	Human Parathyroid Peptide Treatment of Vertebral epporosis International, Vol. 1 Supplement, S199-203, I., "Restoration of Spinal Bone in Osteoporotic Men bein Parathyroid Hormone (1-34) and 1,25-" Journal of Bone and Mineral Research, Vol. 1, No.							
	CS	Slovik, D. M. et al., Treatment With Human Dihydroxyvitamin D," 4, 377-381, (1986).								
	CT	dihydroxyvitamin D to Postmenopausal Women	" Osteoporosis, Vol. 2	one in Osteoporotic Men and 829-835, (1987).						
	CU	Alternating With Calc Spinal Osteoporosis, 17, 421-428, (1987).	citriol Paradoxically Ro " European journal of C	n 1-34 Parathyroid Peptide educe Bone Remodelling in linical Investigation, Vol.						
	CA			s with Human Parathyroid m Fluoride, "BMJ, Vol. 301,						
duplicate o	f CK /		, "Anabolic Actions of views, Vol. 14, No.6, 69	Parathyroid Hormone on 90-709, (1993).						
RHI	СХ			Regimens Other Than Sodium , Vol. 95 supplement 5A, 5A-						
EXAMINER		Puising L.	DATE CONSIDERED	7/29/2002						
MPEP 609;	Draw lin		not in conformance and :	ion is in conformance with not considered. Include copy						

FORM PTO 1445 (modified PRADE Serial No Atty. Docket No. X-11965 09/647,278 INFORMATION DISCLOSURE CITATION Applicant IN AN APPLICATION Janet M. Hock Filing Date Group <del>-1654</del> 9/26/2000 1646 Neer, D.M. et al., "Treatment of Postmenopausal Osteoporosis with Daily CY Parathyroid Hormone Plus Calcitriol, " Osteoporosis International, Vol. 1 RLi Supplement, S204-205, (1993). Whitfield, J.F. et al., "Small Bone-Building Fragments of Parathyroid Hormone: New Therapeutic Agents for Osteoporosis, " TiPS, Vol. 16, 382-386, (1995). Sone, T. et al., "A Small Dose of Human Parathyroid Hormone (1034) CAA Increased Bone Mass in the Lumbar Vertebrae in Patients with Senile Osteoporosis," Miner Electrolyte Metab, Vol. 21, 232-235 (1995). CAB Reginster, J.Y. et al., "Parathyroid Hormone in the Treatment of Involutional Osteoporosis: Back to the Future, " Osteoporosis International, Vol. 7 Supplement 3, S163-S168 (1997). Smith, S.Y. et al., "Efficacy of Recombinant Human Parathyroid Hormone CAC (1-84) (rhPTH, (1-84)) in Ovariectomized Rhesus Monkeys," Journal of Bone and Mineral Research, Vol. 23, No.5, SA456 Abstract, S633, (1998) Finkelstein, J.S. et al., "Increases in bone density after CAD discontinuation of long-term GnRH analog and PTH administration in women with endometriosis, " Journal of Bone and Mineral Research, Vol. 23, Supplement No. 5, F459 Abstract, S518, (1998). CAE Finkelstein, J.S. et al., "Increases in Bone Mineral Density after Discontinuation of Daily Human Parathyroid Hormone and Gonadotriopin-Releasing Hormone Analog Administration in Women with Endometriosis," The Journal of Clinical Endocrinology & Metabolism, Vol. 84, No.4, 1214-1219 (1999). Reeve, J. et al., "The Therapeutic Use of Human Parathyroid Hormone CAF Fragment (hPTH 1-34) in Osteoporosis: Optimizing the Anabolic Effect on Trabecular and Cortical Bone," Monoclonal Antibodies and Developments in Immunoassay, Proceedings of the 3<sup>rd</sup> International Conference on Radioimmunoassay 1981 held in Gardone Riviera, Italy, May 6-9, 1981. 239-246. Finkelstein, J.S. et. al., "Prevention of Estrogen Deficiency-Related CAG Bone Loss With Human Parathyroid Hormone-(1-34), " JAMA, Vol. 280, No. 12, 1067-1073 (1998). Finkelstein, J.S. et al., "Parathyroid Hormone for the Prevention of CAH Bone Loss Induced by Estrogen Deficiency, " The New England Journal of Medicine, Vol. 331, No. 24, 1618-1623, (1994). Hodsman, A.B. et al., "Parathyroid Hormone: The Clinical Experience and Prospects," Chapter 4, 83-108 (1998). CAT CAJ Rittmaster, R.S. et al., "Treatment of Osteoporosis with Parathyroid Hormone Followed by Alendronate. Bone Marker Results, " Bone, Vol. 23, (Suppl.), No.5, S516-S517, Abstract F451, (1998). CAK Lindsay, R. et al., "Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among duplicate of postmenopausal women on oestrogen with osteoporosis, " The Lancet, Vol. 350, 550-555 (1997). CAM CAN CAP EXAMINER DATE CONSIDERED Ruisiang L. 7/29/2002

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

CATION	OSURE CITAT	·	X-1196 Applic Janet Filing 9/26/2	ants M. Hock, e Date	09/647	,278	Filing	
Doc	ſ	U.S. P2	Janet 1 Filing 9/26/2	M. Hock, e Date 000  DOCUMENT	Group <del>1654</del>	Sub-	Filing	
AA .	ument Number		9/26/2	DOCUMENT	1654 S	Sub-	Filing	Date
AA .	ument Number		ATENT			Sub-	Filing	
AA .	cument Number	Date		Name	Class	Sub-	Filing	n Data
		<del></del>	1			class		£
√B							Approp	oriate
/C							<b>-11/</b>	=D
D D						,		
Æ						MAR	1 4 70	02
F						ECH CEI	NTER 16	00/2900
.G								
н				4				
ī				<u> </u>				
J			:					
		FOREIGN	PATENT	DOCUMENTS	<u> </u>	<u> </u>		
Doc	ument Number	Date		Country	Class	Sub- class	Transl	ation
3D 080	73376	19.03.96	JP				yes	no X
BE 083	10965	26.11.96	JP					х
3F			1					
THER DO	CUMENTS (Incl	uding Aut	hor, Ti	tle, Date,	Pertinent Pa	ges. Etc		<u> </u>
	BD 080 BE 083 BF DOG	Document Number  Document Number  BD 08073376  BE 08310965  THER DOCUMENTS (Incl	AF  AG  AH  AI  AI  Document Number Date  BD 08073376 19.03.96  BE 08310965 26.11.96  BF THER DOCUMENTS (Including Aut	FOREIGN PATENT  Document Number Date  BD 08073376 19.03.96 JP  BE 08310965 26.11.96 JP  THER DOCUMENTS (Including Author, Tights)	FOREIGN PATENT DOCUMENTS  Document Number Date Country  BD 08073376 19.03.96 JP  BE 08310965 26.11.96 JP  THER DOCUMENTS (Including Author, Title, Date,	FOREIGN PATENT DOCUMENTS  Document Number Date Country Class  BD 08073376 19.03.96 JP  BE 08310965 26.11.96 JP  THER DOCUMENTS (Including Author, Title, Date, Pertinent Pate)	FOREIGN PATENT DOCUMENTS  Document Number Date Country Class Subclass  BD 08073376 19.03.96 JP  BE 08310965 26.11.96 JP  THER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	FOREIGN PATENT DOCUMENTS    Document Number   Date   Country   Class   Subclass   Yes